Clinical trial platform company Slope is joining the White House’s Cancer Moonshot initiative as a founding member of the public-private partnership CancerX.
Slope will help accelerate cancer clinical trials using its technology that speeds study startup and close-out and aids sites in ensuring they have all the resources they need, according to a Friday press release.
The Cancer Moonshot aims to reduce cancer deaths by 50% over the next 25 years. CancerX was announced by President Joe Biden in February to bring together industry and other stakeholders to drive digital innovation in the fight against cancer. The inaugural project involves driving down the cost of care using digital solutions.
CancerX is a joint initiative of the Moffitt Cancer Center, the Digital Medicine Society, the Office for the National Coordinator for Health Information Technology and the Office of the Assistant Secretary for Health.
Slope’s clinical trial execution technology is used by top pharma companies, biotechs and CROs, the company said.